Catania, October 1 2018 – SIFI, Italian leader in the development of therapeutic solutions to treat ophthalmic disorders, announces that it has appointed Andrea Quaglino as new Chief Financial Officer of the Company, as of today. Andrea Quaglino will report to Fabrizio Chines, CEO.
Following a long career in audit with Deloitte & Touche, Andrea Quaglino, has held the role of CFO in Molmed SpA, a biotech company listed on the Milan stock exchange since 2008, where he has successfully completed several extraordinary operations of capital increase.
"We are pleased that Andrea, a professional with significant international experience and proven skills, has decided to join the SIFI team, confiding in our development project." said Fabrizio Chines, Chairman and Chief Executive Officer "We are sure that he will bring added value to our Group in order to achieve our objectives of innovation and internationalization, helping us to achieve SIFI's strategic vision".
SIFI
SIFI is the leading Italian ophthalmic company, focused on eye care since 1935. SIFI designs, manufactures and markets innovative pharmaceutical specialty products, surgical and medical devices. Headquartered in Catania, Sicily, SIFI operates directly in Italy, Romania and Mexico with a staff of more than 370 people worldwide. Since June 2015, SIFI is backed by 21 Investimenti, a private equity firm founded by Alessandro Benetton, which supports the company’s international expansion and portfolio development strategy. More information available at www.sifigroup.com.
For information:
Press & Communication SIFI
press@sifigroup.com
Ada Puglisi 0039 095 7922145
